Gufic Biosciences Limited (GUFICBIO.BO)

INR 449.05

(0.28%)

Market Cap (In INR)

45.02 Billion

Revenue (In INR)

8.06 Billion

Net Income (In INR)

861.35 Million

Avg. Volume

11.16 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
278.0-501.1
PE
-
EPS
-
Beta Value
0.796
ISIN
INE742B01025
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Pranav Jayesh Choksi
Employee Count
-
Website
https://www.gufic.com
Ipo Date
2001-03-05
Details
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. The company manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. It manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, the company offers spark, criti care, criticare life, and ferticare pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. It supplies its products to hospital chains and medical facilities. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.